CareDx (CDNA) Projected to Post Earnings on Tuesday

CareDx (NASDAQ:CDNA) is anticipated to issue its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect the company to announce earnings of $0.24 per share and revenue of $102.7560 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:30 PM ET.

CareDx Trading Up 2.8%

Shares of CDNA stock opened at $19.63 on Tuesday. The company has a market capitalization of $1.01 billion, a price-to-earnings ratio of 16.50 and a beta of 2.51. The firm has a 50-day moving average price of $19.73 and a 200 day moving average price of $16.45. CareDx has a twelve month low of $10.96 and a twelve month high of $25.55.

Insider Buying and Selling at CareDx

In other news, CEO John Walter Hanna, Jr. sold 19,280 shares of CareDx stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $21.16, for a total value of $407,964.80. Following the transaction, the chief executive officer directly owned 597,405 shares of the company’s stock, valued at $12,641,089.80. The trade was a 3.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Over the last quarter, insiders sold 29,636 shares of company stock valued at $625,949. Insiders own 4.40% of the company’s stock.

Institutional Investors Weigh In On CareDx

Several institutional investors have recently bought and sold shares of the business. Quarry LP purchased a new position in CareDx in the fourth quarter valued at about $25,000. Meeder Asset Management Inc. purchased a new position in CareDx in the 4th quarter valued at about $79,000. Quantbot Technologies LP acquired a new stake in shares of CareDx during the third quarter valued at about $89,000. Tower Research Capital LLC TRC increased its position in shares of CareDx by 120.6% during the second quarter. Tower Research Capital LLC TRC now owns 7,608 shares of the company’s stock worth $149,000 after acquiring an additional 4,160 shares during the last quarter. Finally, State of Wyoming acquired a new position in shares of CareDx in the fourth quarter worth about $155,000.

Analyst Ratings Changes

A number of brokerages recently issued reports on CDNA. Wells Fargo & Company raised their target price on shares of CareDx from $14.00 to $18.00 and gave the stock an “equal weight” rating in a research report on Monday, December 15th. BTIG Research raised their price objective on CareDx from $22.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Wall Street Zen downgraded CareDx from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Craig Hallum cut CareDx from a “buy” rating to a “hold” rating and set a $26.00 price target for the company. in a report on Tuesday, January 6th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of CareDx in a research note on Monday, December 29th. Three research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, CareDx has a consensus rating of “Hold” and a consensus price target of $26.67.

About CareDx

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.